Clinical Trials List
2013-09-01 - 2017-05-31
Phase II
Terminated4
-
Trial Applicant
BAYER TAIWAN COMPANY LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Chih-Hung Hsu Division of Hematology & Oncology
- PEI-JER CHEN Division of Hematology & Oncology
- - - Division of Radiology
- Ann-Lii Cheng Division of Hematology & Oncology
- SHIH-HUNG YANG Division of Hematology & Oncology
- Jih-Hsiang Lee Division of Hematology & Oncology
- YU-YUN SHAO Division of Hematology & Oncology
- Ming-Chih Ho Division of Hematology & Oncology
- 林宗哲 Division of Hematology & Oncology
- Chien-Hung Chen Division of Hematology & Oncology
- SHIH-HUNG YANG Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Chau-Ting Yeh Digestive System Department
- Chao-Wei Hsu Digestive System Department
- Shi-Ming Lin Digestive System Department
- Wei-Chen Lee Division of General Surgery
- 呂嘉偉 Division of Radiology
- Ming-Chin Yu Division of General Surgery
- Tsai-Sheng Yang Division of Hematology & Oncology
- Yi-Cheng Chen Digestive System Department
- 陳威廷 Digestive System Department
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 陳威宇 Division of Hematology & Oncology
- Shang-Hung Chen Division of Hematology & Oncology
- 林明賢 Division of Hematology & Oncology
- Shang-Wen Chen Division of Hematology & Oncology
- 黃文聰 Division of Hematology & Oncology
- 林建良 Division of Hematology & Oncology
- 曹朝榮 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
- 陳彥勳 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Wei-Pang Chung Division of Hematology & Oncology
- Shang-Yin Wu Division of Hematology & Oncology
- Yu-Min Yeh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
100 participants
-
Global
2650 participants